Forbion is a leading global venture capital firm with deep expertise in Europe. We invest in innovative biotech companies, managing just over €5 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. In addition, we leverage our biotech expertise beyond human health to address ‘planetary health’ challenges through our BioEconomy fund strategy, which invests in companies developing sustainable solutions in food, agriculture, materials, and environmental technologies.
Our team consists of over 30 investment professionals that have built an impressive performance track record since the late nineties with 128 investments across 11 funds. We select impactful investments that will positively affect the health and well-being of people and the planet, as well as meet its financial return objectives. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.
